Pharsight

Kynamro patents expiration

KYNAMRO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6222025 KASTLE THERAPS LLC Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
Mar, 2015

(9 years ago)

US5914396 KASTLE THERAPS LLC 2'-O-modified nucleosides and phosphoramidites
Jun, 2016

(7 years ago)

US6451991 KASTLE THERAPS LLC Sugar-modified gapped oligonucleotides
Feb, 2017

(7 years ago)

US6166197 KASTLE THERAPS LLC Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
Dec, 2017

(6 years ago)

US7407943 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Aug, 2021

(2 years ago)

US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(1 year, 2 months ago)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(9 months ago)

Kynamro is owned by Kastle Theraps Llc.

Kynamro contains Mipomersen Sodium.

Kynamro has a total of 8 drug patents out of which 7 drug patents have expired.

Expired drug patents of Kynamro are:

  • US6222025
  • US5914396
  • US6451991
  • US6166197
  • US7407943
  • US7015315
  • US7101993

Kynamro was authorised for market use on 29 January, 2013.

Kynamro is available in solution;subcutaneous dosage forms.

Kynamro can be used as adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with homozygous familial hypercholesterolemia.

Drug patent challenges can be filed against Kynamro from 29 January, 2017.

The generics of Kynamro are possible to be released after 29 January, 2027.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-41) Jan 29, 2020
Orphan Drug Exclusivity(ODE) Jan 29, 2020
New Chemical Entity Exclusivity(NCE) Jan 29, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MIPOMERSEN SODIUM ingredient

NCE-1 date: 29 January, 2017

Market Authorisation Date: 29 January, 2013

Treatment: Adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with h...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

KYNAMRO family patents

Family Patents